These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. Chambers MS; Rugo HS; Litton JK; Meiller TF J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772 [TBL] [Abstract][Full Text] [Related]
5. Clinical presentation and management of mTOR inhibitor-associated stomatitis. de Oliveira MA; Martins E Martins F; Wang Q; Sonis S; Demetri G; George S; Butrynski J; Treister NS Oral Oncol; 2011 Oct; 47(10):998-1003. PubMed ID: 21890398 [TBL] [Abstract][Full Text] [Related]
6. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486 [TBL] [Abstract][Full Text] [Related]
8. Nursing care for oral complications associated with chemotherapy. A survey among members of the Dutch Oncology Nursing Society. Nieweg R; van Tinteren H; Poelhuis EK; Abraham-Inpijn L Cancer Nurs; 1992 Oct; 15(5):313-21. PubMed ID: 1423250 [TBL] [Abstract][Full Text] [Related]
9. Reducing the incidence of stomatitis using a quality assessment and improvement approach. Graham KM; Pecoraro DA; Ventura M; Meyer CC Cancer Nurs; 1993 Apr; 16(2):117-22. PubMed ID: 8477399 [TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Shameem R; Lacouture M; Wu S Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371 [TBL] [Abstract][Full Text] [Related]
11. The importance of assessment rating scales for chemotherapy-induced oral mucositis. Jaroneski LA Oncol Nurs Forum; 2006 Nov; 33(6):1085-90; quiz 1091-3. PubMed ID: 17149392 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy: the effect of oral cryotherapy on the development of mucositis. Karagözoğlu S; Filiz Ulusoy M J Clin Nurs; 2005 Jul; 14(6):754-65. PubMed ID: 15946284 [TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Kalogirou EM; Tosios KI; Piperi EP; Sklavounou A Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e13-9. PubMed ID: 25442249 [TBL] [Abstract][Full Text] [Related]
18. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Sonis S; Andreotta PW; Lyng G Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917 [TBL] [Abstract][Full Text] [Related]
19. Assessment of oral mucositis in adult and pediatric oncology patients: an evidence-based approach. Farrington M; Cullen L; Dawson C ORL Head Neck Nurs; 2010; 28(3):8-15. PubMed ID: 20863028 [TBL] [Abstract][Full Text] [Related]
20. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Lo Muzio L; Arena C; Troiano G; Villa A Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]